...chromosomal aneuploidies within the 3q26 region in cytological specimens revealing low grade intraepithelial lesions (LSIL). Ikonisys Inc....

...Enzo's Enzo Clinical Lab received exclusive rights to market Ikonisys' oncoFISH cervical cancer diagnostic to physicians...
...York and New Jersey. Financial terms were not disclosed. Enzo Biochem Inc. (NYSE:ENZ), Farmingdale, N.Y. Ikonisys Inc....

...FDA approved a 510(k) application from Ikonisys for its oncoFISH her2 test to detect HER2 status...
...processed with the PathVysion Her2 DNA Probe Kit from Abbott Laboratories (NYSE:ABT, Abbott Park, Ill.). Ikonisys Inc....

...is used to assess the risk of progression of low grade dysplasia to cervical cancer. Ikonisys Inc....

...effect of the mutation, which is predicted to be involved in the protein N-glycosylation process. Ikonisys Inc....

...of the mutations and how defects in OTase can nevertheless result in normal cellular N-glycosylation. Ikonisys Inc....

...in detecting trisomy 21 in circulating fetal cells of pregnant women during the first trimester. Ikonisys Inc....

...Molecular diagnostics company Ikonisys (New Haven, Conn.) raised $30 million in a series E round. New...

...Ben Kaplan as SVP and CFO, formerly SVP of finance and administration and CFO at Ikonisys Inc....